Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Graft vs Host Disease

pyrazines has been researched along with Graft vs Host Disease in 48 studies

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (31.25)29.6817
2010's32 (66.67)24.3611
2020's1 (2.08)2.80

Authors

AuthorsStudies
Cao, X; Liu, X; Xia, S; Xu, S1
Cardona, DM; Cardones, AR; Chao, NJ; Chen, BJ; Di Paolo, JA; Jia, W; Kim, JY; Perez, VL; Poe, JC; Reyes, NJ; Saban, DR; Sarantopoulos, S; Su, H; Sundy, JS1
Du, X; Geng, S; Lai, P; Lin, S; Ling, W; Liu, X; Luo, C; Lv, M; Weng, J1
Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D1
Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D1
McNeil, C1
Childs, R; Cook, L; Jaffe, ES; Ramos, C; Vo, P1
Al-Homsi, AS; Kouttab, N; Lai, Z; Roy, TS1
Gahrton, G; Krishnan, A1
Al-Homsi, AS; Al-Malki, MM; Junghans, RP; Kouttab, N; Lai, Z; Roy, TS1
Cheng, Q; Jin, Y; Liang, Y; Liu, H; Ma, S; Wang, Y; Wu, D; Wu, Y; Zhang, Y; Zheng, D1
Abedi, M; Ames, E; Blazar, BR; Chen, M; Grossenbacher, SK; Jagdeo, J; Mirsoian, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ1
Abedi, M; Blazar, BR; Chen, M; Hagino, T; Hsiao, HH; Mall, C; Monjazeb, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J1
Magenau, JM; Reddy, P1
Almeida, J; Blanco, B; Del Cañizo, C; García-Briñón, J; Herrero-Sánchez, MC; Inogés, S; Rodríguez-Serrano, C; San-Segundo, L; SanMiguel, JF; Santos-Briz, Á1
Alyea, EP; Antin, JH; Armand, P; Cutler, C; Garcia, M; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ; Stevenson, KE1
Li, ZY; Lu, QX; Pan, XY; Sun, HY; Wu, SH; Xu, KL1
Hoevenaren, A; Hoevenaren, IA; Levenga, H; Minnema, MC; Raymakers, R; van Vulpen, LF1
Vokurka, S1
Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M1
Einsele, H; Knop, S; Kortüm, M1
Fang, Y; Tao, Y; Wang, J; Wang, L; Yang, D; Zhang, W; Zhou, H1
Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR1
Gahrton, G1
Blanco, B; Caballero-Velázquez, T; Inogés, S; Pérez-Simón, JA; Sánchez-Abarca, LI; Santamaría, C1
Bosi, A; Bruno, B; Corradini, P; Einsele, H; Fanin, R; Festuccia, M; Isola, M; Morabito, F; Nozza, A; Nozzoli, C; Patriarca, F; Sperotto, A; Spina, F; Stuhler, G1
de Lima, M; Koreth, J; Reddy, P1
Blanco, B; Caballero-Velázquez, T; Calderon, C; Carrancio, S; del Cañizo, C; Gutierrez-Cosio, S; Herrero, C; Pérez-Simón, JA; San Miguel, JF; Sánchez-Abarca, LI; Serrano, C1
Augusti, V; Ballestrero, A; Carbone, F; Moran, E; Nencioni, A; Patrone, F1
Giralt, S1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, C; Ho, VT; Kim, HT; Koreth, J; McDonough, SM; Ritz, J; Soiffer, RJ; Stevenson, KE1
Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P1
Liang, Y; Liu, H1
Cen, XN; Dong, YJ; Li, Y; Liu, W; Qiu, ZX; Ren, HY; Shi, YJ; Wang, LH; Yin, Y1
Barao, I; Blazar, BR; Liu, H; Murphy, WJ; O'Shaughnessy, MJ; Panoskaltsis-Mortari, A; Riordan, W; Sayers, TJ; Serody, JS; Sitcheran, R; Sun, K; Welniak, LA; Wysocki, C1
Anver, MR; Blazar, BR; Murphy, WJ; Panoskaltsis-Mortari, A; Sayers, TJ; Sun, K; Welniak, LA; Wilkins, DE1
Drobyski, WR; Hari, P; Jacobs, P; Komorowski, R; Vodanovic-Jankovic, S1
Alberca, M; Blanco, B; Carvajal-Vergara, X; López-Holgado, N; Maiso, P; Mateos, J; Pandiella, A; Pérez-Simón, JA; San Miguel, J; Sánchez-Abarca, LI; Schenkein, D; Vidriales, B; Villarón, E1
Chim, CS; Ooi, GC1
Ayuk, FA; Corradini, P; Goldschmidt, H; Hegenbart, U; Kröger, N; Lokhorst, HM; Montefusco, V; Nagler, A; Perez-Simon, JA; Raymakers, RA; San Miguel, JF; van de Donk, NW; van Oers, MH; Verdonck, LF; Zijlmans, M1
Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A1
Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F1
Janssen, JJ; Lokhorst, HM; Zweegman, S1
Castagna, L; Mazza, R; Nozza, A; Rahal, D; Santoro, A; Sarina, B; Todisco, E1
Barlogie, B; Crowley, J; van Rhee, F1
Etxebarria, J; Hernández, E; Lopez, O; Mateos-Mazon, J; Pérez-Simón, JA; San Miguel, JF1
Blaise, D; de Lavallade, H; El-Cheikh, J; Faucher, C; Fürst, S; Hardan, I; Michallet, M; Mohty, M; Nagler, A; Nicolini, FE; Revesz, D; Shimoni, A; Sobh, M1

Reviews

7 review(s) available for pyrazines and Graft vs Host Disease

ArticleYear
Allogeneic transplantation in multiple myeloma.
    Expert review of hematology, 2014, Volume: 7, Issue:1

    Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Gamma Rays; Graft vs Host Disease; Histocompatibility Testing; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous

2014
[Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transplantation, Homologous

2010
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
    Future oncology (London, England), 2011, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Disease; Humans; Immunomodulation; Models, Animal; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous

2011
Emerging therapies in hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:1 Suppl

    Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat

2012
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Animals; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
    Current pharmaceutical design, 2013, Volume: 19, Issue:18

    Topics: Animals; Antibodies; B-Lymphocytes; Boronic Acids; Bortezomib; Dendritic Cells; Drug Design; Graft Rejection; Graft vs Host Disease; Humans; Organ Transplantation; Proteasome Inhibitors; Pyrazines; T-Lymphocytes

2013
Proteasome inhibitors: antitumor effects and beyond.
    Leukemia, 2007, Volume: 21, Issue:1

    Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction

2007

Trials

8 trial(s) available for pyrazines and Graft vs Host Disease

ArticleYear
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2013
Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB.
    Transplant immunology, 2014, Volume: 30, Issue:1

    Topics: Antigen Presentation; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclophosphamide; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Humans; I-kappa B Proteins; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; NF-kappa B; Postoperative Care; Pyrazines

2014
Treatment of chronic graft-versus-host disease with bortezomib.
    Blood, 2014, Sep-04, Volume: 124, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Scleroderma, Systemic; Skin; Transplantation, Homologous; Treatment Outcome; Tumor Cells, Cultured

2014
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines

2014
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
    Blood, 2009, Oct-29, Volume: 114, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Methotrexate; Pyrazines; Stem Cell Transplantation; Survival Rate; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous

2009
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26

    Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Pyrazines; Tacrolimus; Unrelated Donors

2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors

2013
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
    Experimental hematology, 2006, Volume: 34, Issue:6

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous

2006

Other Studies

33 other study(ies) available for pyrazines and Graft vs Host Disease

ArticleYear
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
    Cellular & molecular immunology, 2020, Volume: 17, Issue:10

    Topics: Acute Disease; Agammaglobulinaemia Tyrosine Kinase; Anemia, Aplastic; Animals; Benzamides; Bone Marrow; Cell Proliferation; Graft vs Host Disease; Lymphocyte Activation; Mice, Inbred BALB C; Mice, Inbred C57BL; Phospholipase C gamma; Phosphorylation; Pyrazines; Receptors, Antigen, T-Cell; T-Lymphocytes

2020
SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.
    JCI insight, 2018, 10-04, Volume: 3, Issue:19

    Topics: Administration, Oral; Animals; B-Lymphocytes; Disease Models, Animal; Drug Evaluation, Preclinical; Eye; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Indazoles; Mice; Protein Kinase Inhibitors; Pyrazines; Skin; Survival Analysis; Syk Kinase; T-Lymphocytes; Treatment Outcome

2018
Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease.
    Clinical laboratory, 2013, Volume: 59, Issue:1-2

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; T-Lymphocytes, Regulatory

2013
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
    Bone marrow transplantation, 2013, Volume: 48, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
    Journal of the National Cancer Institute, 2013, Jul-03, Volume: 105, Issue:13

    Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat

2013
Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Interferons; Lymph Nodes; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Rituximab; Transplantation, Homologous

2013
Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB.
    Transplant immunology, 2013, Volume: 29, Issue:1-4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Humans; I-kappa B Kinase; NF-kappa B; Proteasome Inhibitors; Pyrazines

2013
IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Feb-01, Volume: 192, Issue:3

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Transplantation; Cyclophosphamide; Cytokines; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Pyrazines; Signal Transduction; Specific Pathogen-Free Organisms; Spleen; Toll-Like Receptor 4; Transplantation Conditioning; Whole-Body Irradiation

2014
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Acute Disease; Animals; Antibodies, Neutralizing; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Disease Models, Animal; Female; Graft vs Host Disease; Interleukin-6; Liver Diseases; Mice; Organ Specificity; Pyrazines; Skin Diseases

2014
Proteasome: target for acute and chronic GVHD?
    Blood, 2014, Sep-04, Volume: 124, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Pyrazines

2014
Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
    British journal of haematology, 2016, Volume: 173, Issue:5

    Topics: Animals; Cells, Cultured; Female; Graft vs Host Disease; Humans; Imidazoles; Immune Tolerance; Lymphocyte Activation; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Multiprotein Complexes; Pyrazines; T-Lymphocytes; TOR Serine-Threonine Kinases

2016
[Effect of bortezomib on acute graft-versus-host disease in mice model and its mechanism].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:6

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Disease Models, Animal; Female; Graft vs Host Disease; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Tumor Necrosis Factor-alpha

2009
Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
    Bone marrow transplantation, 2011, Volume: 46, Issue:2

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Tissue Donors; Transplantation, Homologous

2011
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
    International journal of hematology, 2010, Volume: 92, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult

2010
Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells.
    Experimental hematology, 2011, Volume: 39, Issue:6

    Topics: Acute Disease; Animals; Boronic Acids; Bortezomib; Cytokines; Dendritic Cells; Flow Cytometry; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines

2011
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous

2011
Allogeneic transplantation in multiple myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2011
Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
    Leukemia research, 2011, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Vitro Techniques; Interferon-gamma; Lymphocyte Activation; Lymphocyte Depletion; Proteasome Inhibitors; Pyrazines; T-Lymphocytes; Transplantation, Homologous

2011
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous

2012
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
    Haematologica, 2012, Volume: 97, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Female; Flow Cytometry; Graft vs Host Disease; Graft vs Tumor Effect; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Pyrazines; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Transplantation, Homologous

2012
Graft-versus-host disease: have we solved the problem?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26

    Topics: Antigens, CD34; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Pyrazines; Siblings; T-Lymphocyte Subsets

2012
Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Adult; Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Chemokine CCL19; Chemokine CXCL9; Chemotaxis; Depression, Chemical; Down-Regulation; Drug Evaluation, Preclinical; Graft vs Host Disease; Humans; Lymphocyte Activation; Mitogen-Activated Protein Kinase 1; Phosphorylation; Protease Inhibitors; Protein Processing, Post-Translational; Pyrazines; Receptors, CCR7; Receptors, CXCR3; T-Lymphocyte Subsets

2012
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, May-25, Volume: 101, Issue:21

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Protease Inhibitors; Pyrazines; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Homologous

2004
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
    Blood, 2005, Nov-01, Volume: 106, Issue:9

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Enzyme Inhibitors; Female; Gastrointestinal Tract; Graft vs Host Disease; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger

2005
NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.
    Blood, 2006, Jan-15, Volume: 107, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Colon; Cytokines; Graft Survival; Graft vs Host Disease; H-2 Antigens; Heterocyclic Compounds, 3-Ring; Leukocyte Common Antigens; Mice; Mice, Knockout; NF-kappa B; Pyrazines; Pyridines; Survival Rate

2006
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
    Blood, 2006, May-01, Volume: 107, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cytokines; Graft vs Host Disease; Humans; In Vitro Techniques; Isoantigens; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Protease Inhibitors; Pyrazines; T-Lymphocytes; Th1 Cells

2006
Bulbar palsy in multiple myeloma.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine

2005
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
    Blood, 2006, Apr-15, Volume: 107, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous

2006
Immune-modulatory effects of bortezomib in GVHD.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Graft vs Host Disease; Humans; Immune System; Inflammation; Multiple Myeloma; NF-kappa B; Plasmacytoma; Pyrazines; Spleen; Stem Cell Transplantation; T-Lymphocytes; Transplantation, Homologous

2007
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chronic Disease; gamma-Glutamyltransferase; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction

2007
Allografting or autografting for myeloma.
    The New England journal of medicine, 2007, Jun-21, Volume: 356, Issue:25

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Survival Rate; Transplantation, Autologous; Transplantation, Homologous

2007
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
    Haematologica, 2007, Volume: 92, Issue:9

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2007
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Fatigue; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2008